This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): OraceaCol-101, doxycycline
Description: Oracea is a modified-release formulation of doxycycline, an antibiotic that inhibits protein synthesis and bacterial growth by binding to the 30S ribosomal sub-unit of the protein synthesis machinery.
Deal Structure: In December 2006, CollaGenex signed a License and Supply Agreement with MediGene AG for the right to manufacture, register, market and sell Oracea in the European Union, certain contiguous countries and Russia. CollaGenex is entitled to an upfront fee of $5 million upon signing of the agreement as well as an additional $7.5 million in milestone payments upon the achievement of certain annual sales thresholds. In addition, CollaGenex will receive a royalty of 12% of annual net sales up to $10 million and 15% of annual net sales in excess of $10 million.
In February 2008, CollaGenex Pharmaceuticals announced that it entered into a definitive merger agreement with an affiliate of Galderma Pharma S.A. Upon completion of the merger, CollaGenex will become a wholly-owned subsidiary of Galderma.
In April 2008, CollaGenex became a wholly-owned subsidiary of Galderma.
In July 2008, MediGene AG sold the European rights of Oracea for the treatment of rosacea to Galderma Laboratories,...See full deal structure in Biomedtracker
Partners: MediGene AG
Additional information available to subscribers only: